COMPANY Compumedics (CMP)
MCAP A$116m
$0.66/share
Date: 5 September 2019
RECOMMENDATION Buy | PT $0.95/share | High Risk
EVENT FY19 | Tangible brain diagnostic platform with blue sky
KEY POINTS
·FY’19 EBITDA of $5.9m is the first significant lift after four years of $4m to $5m. 2H’19’s $4.5m is 55% bigger than any other HY.
·We estimate the Base sleep & neuro diagnostics delivered $6.2m and the first breakeven result from Step-outs of -$0.3m with two parts delivering cash(MEG $0.2m, eHealth $0.5m, SomFit -$1.0m)
·After success of two Step-outs and Base we stay with our forecast of a significant ramp-up over three years to EBITDA of $20m, with 30% from Base and 70% from Step-outs
·CMP has set a conservative FY’20 EBITDA target of $6.5m to $7.5m without any contribution from MEG. Our report tries to show the three steps to link FY’19 $5.9m to $20m over 3 years.
FY’21F METRICS PER 12.4x | EV/EBITDA 8.5x | Yield 2%
LINK TO RESEARCH REPORT RR_CMP_050919 (6 pages)
OPPORTUNITIES TO MEET CMP MANAGEMENT - Please contact PAC Partners representative
Tuesday 10 September - Melbourne
Tuesday 8 October - Sydney
INVESTMENT VIEWWe retain a Buy on CMP and expect it to re-rate towards $0.95/share as:
- Base (sleep & neuro diagnostic devices & services) deliver reliable growth over next two halves with the dual premium and mid offers, and eHealth moves into growth leverage after the USA backbone build.
- Blue sky from Step-outs becomes more tangible with new orders of MEG in 2H’20F and a distribution partner for SomFit.
COMPANY BACKGROUND
Compumedics (CMP) is a leading supplier of sleep and neurological diagnostic devices globally, with around 23k units installed and 1,500 units sold annually for $9k to $25k. 15-20% of group sales come from recurring services for existing units. CMP has captured around 30-40% of the premium end of sleep and neurological clinics across Nth America, Europe and China/Japan/Australia.
Since 2012 CMP has developed a lower cost solution for sleep/diagnostics with simpler units and an eHealth platform for the smaller testing centres.
CMP has also upskilled its neurological devices to move from a software supplier to 100 (of 130) ~A$5m Orion MEG <MagnetoEncephaloGraphy> machines to a supplier of the full device with Korean Partner (KRISS). The first Orion MEG was installed in reference Barrow Institute in Arizona USA in 2019.
CMP will take a simple sleep diagnostic device (SomFit) to the retail market, and would prefer to do with a consumer goods partner.
KEY DRIVERS
·Sleep and neuro diagnostic growth in clinics (hardware & software) and smaller centres (amplifier & cloud)
·Brain wave diagnostics for autism, dementia & other neurological conditions require a 10x faster and more accurate MRI which is a new machine (MEG MagnetoEncephaloGraphy)
·Consumer sleep testing with simplified sensor (SomFit)
MILESTONES
·FY’20F - US Adventist Health hospital orders and boost to low cost diagnostic sales
·FY’20F MEG – FDA approval and two new orders in 2H
·FY’20F SomFit – Distribution partner by 4Q
·FY’22F: $20m EBITDA
- Forums
- ASX - By Stock
- CMP
- Ann: Record Revenues and Profit Up
Ann: Record Revenues and Profit Up, page-9
Featured News
Add CMP (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.5¢ |
Change
0.015(5.17%) |
Mkt cap ! $56.04M |
Open | High | Low | Value | Volume |
29.0¢ | 30.5¢ | 29.0¢ | $23.13K | 78.20K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 19542 | 29.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.5¢ | 115 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 19542 | 0.290 |
1 | 3000 | 0.280 |
1 | 4000 | 0.275 |
1 | 3484 | 0.270 |
1 | 25000 | 0.265 |
Price($) | Vol. | No. |
---|---|---|
0.305 | 115 | 1 |
0.310 | 30000 | 1 |
0.320 | 25725 | 2 |
0.340 | 38715 | 2 |
0.350 | 3333 | 1 |
Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
Featured News
CMP (ASX) Chart |